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experience, including preference for GLM and the auto-injector over previousmed-
ication and injection device.
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OBJECTIVES: To examine the association between access restrictions on celecoxib
use and healthcare costs in Medicare patients with arthritis.METHODS: Enrollees
diagnosed with osteoarthritis (OA) or rheumatoid arthritis (RA) between January 1,
2008 and December 31, 2010 (index date) and at least 24 months of continuous
health plan enrollment (I-year pre- and post-index date) were identified from 12
health plans with and without access restrictions to celecoxib in the MarketScan®
Medicare Supplemental and Coordination of Benefits Database. Utilization of celecoxib,
all-cause, gastrointestinal (GI) event-related, and OA/RA-related healthcare utili-
zation and expenditures over a 12-month follow-up period were compared for
enrollees in restricted and unrestricted plans. RESULTS: The restricted group
(N27,595) was similar to the unrestricted group (N57,890) at baseline in terms of
the prevalence of OA/RA, serious GI events, and Charlson Comorbidity Index (CCI)
score; however, celecoxib use was significantly lower in the restricted group (11.8%
vs. 13.5%, p0.001). Total baseline medical costs were significantly higher for the
restricted group as compared to the unrestricted group ($13,641 vs. $10,456,
p0.001), whereas pharmacy costs were lower ($3,873 vs. $4,488, p0.001) for the
restricted group. No differenceswere observed between the two groups inGI event-
related costs ($643 vs. $602, p0.127). Total OA/RA related costs were significantly
higher in the restricted group than the unrestricted group ($9,432 vs. $6,642,
p0.001), which were primarily driven by inpatient costs ($6,215 vs. $3,857,
p0.001). All-cause total costs were also significantly higher in the restricted group
than in the unrestricted group ($25,428 vs. $20,793, p0.001), which were primarily
driven by the costs of inpatient and outpatient services. CONCLUSIONS: Enrollees
in plans with access restrictions to celecoxib had lower utilization of celecoxib. No
differences were observed between the groups in GI event-related costs. All-cause
and OA/RA-related costs, howver, were significantly higher among enrollees in
plans with access restrictions.
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OBJECTIVES: To evaluate the utilization patterns of Medicare Part D beneficiaries
newly started on teriparatide and the association of adherence with fracture out-
comes and health care utilization.METHODS: A retrospective cohort analysis was
performed using medical and pharmacy claims of 761 Humana members aged 18
and older with first prescription fills for teriparatide between January 2008 and
December 2009. Low Income Subsidy enrollees were excluded. Descriptive analy-
ses summarized baseline characteristics, healthcare use, and costs at 12 and 24
months post teriparatide initiation. Adherence was measured by Proportion of
Days Covered (PDC), categorized as high (PDC 80%), intermediate (50% PDC
80%), and low (PDC50%). Multivariate logistic regression was used to evaluate
associations of adherence with fracture rates. RESULTS: Six months before teripa-
ratide initiation, 50.7% of the cohort (386 patients) had at least 1 fracture episode,
although there was low overall comorbidity (Deyo Charlson mean 1.1). At 12
months, 21% of the cohort was highly adherent, whereas at 24 months, only 13%
was highly adherent (272 patients). More low adherent patients visited the ER or
had inpatient visits at 12 months than highly adherent patients (33% vs. 24%;
p0.05; 21% vs. 16%; NS). Total health care costs were greater at 12 months in
highly-adherent patients ($21,033 vs. $15,528; p0.05). Among thehighly adherent,
64%of costswas pharmacy-related. At 12months, only 18%of the 222 patientswith
fractures was highly adherent; this group had the highest overall fracture-related
costs, of which 89% was pharmacy-related. The regression models demonstrated
no significant association between teriparatide adherence and 12-month fracture
outcomes (OR0.81, 95% C.I. 0.53 – 1.24). CONCLUSIONS: Similar to previous stud-
ies of patients with osteoporosis, adherence to prescribed therapywas suboptimal.
Highly-adherent patients appeared to have higher overall costs due to higher phar-
macy costs, whereas patients with low adherence had higher health care utiliza-
tion.
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OBJECTIVES: To estimate national and regional dose escalation patterns over two
years of therapy among biologic naïve RA patients initiating etanercept, adali-
mumab, or infliximab using US managed care data.METHODS: Adult (ages 18-65)
RA patients who did not use RA biologics in the prior six months, initiating etan-
ercept, adalimumab, or infliximab between July 1, 2005 and April 30, 2009 were
identified using the MarketScan® Commercial Database. National and regional
dose escalation rates were evaluated 12 and 24 months after initiation using the
Single Instance Method (one claim with an average weekly dose at least 115%,
130%, or 150% greater than the initial weekly dose) and the Two Instances Method
(two consecutive claims with an average weekly dose 130% greater than the initial
weekly dose). Dose escalation rates were compared using Fisher’s Exact tests.
RESULTS: A total of 2,747 patients met the inclusion criteria (mean age 50 years
(SD10), 74% female). More patients resided in the South (45%) than North Central
(28%), West (17%) or East (10%) US regions. More patients (44%) initiated etanercept
than adalimumab (37%) or infliximab (20%). In the first year of therapy, dose esca-
lation ranged from 0.8%-1.5% for etanercept, 10.8%-12.5% for adalimumab, and
16.4%-42.5% for infliximab using the single instance method; ranges at 24 months
were 0.8%-2.1% for etanercept, 14.3%-17.5% for adalimumab, and 26.4%-57.6% for
infliximab. At 12 and 24 and months respectively, the two instances method
showed lower dose escalation rates for etanercept (0.8%, 0.8%) than adalimumab
(8.7%, 13.3%) or infliximab (22.9%, 37.6%) at the 130% threshold (p0.001). Dose
escalation rates were consistent across US geographic regions, with etanercept
having less dose escalation than adalimumab or infliximab across all regions.
CONCLUSIONS: RA patients initiating etanercept had lower dose escalation rates
than patients initiating adalimumab or infliximab in the first and second year
following therapy initiation and across US geographic regions.
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OBJECTIVES: To estimate dose escalation rates of etanercept, adalimumab, and
infliximab for RA patients initiating and continuing TNF-blockersMETHODS: This
retrospective analysis in the HealthCore Integrated Research Database identified
adult (18-64 years) RA patients with 1 claim for etanercept, adalimumab, or inf-
liximab between July 1, 2007 and January 31, 2010 (first claimindex). Patientswere
continuously enrolled for 6 months prior to index; patients with TNF-blocker
claims within 6 months prior to index were considered continuing therapy. Pa-
tients with other indicated conditions or contraindicated to RA biologic therapy
were excluded. Dose escalation, assessed over a 12-month period of continuous
treatment (60-day gap), was defined as: 1) 2 instances in which subsequent
doses were 130% of index dose or 2) any instances with increased number of
syringe/vial or shortened dosing interval. RESULTS: Overall, 3868 patients were
included (mean age 50.1 years; 74.4% female). Among newpatients (932 etanercept;
267 adalimumab; 292 infliximab), 4.4%, 9.0%, and 42.5% of etanercept, adalimumab,
and infliximab patients, respectively, had 2 instances of dose escalation (p0.001
for all 2-way comparisons). Most new patients (85.3% etanercept; 92.1% adali-
mumab; N/A infliximab) initiated therapy at recommended dose; of these patients,
2.3%, 12.6%, and 59.9% of etanercept, adalimumab, and infliximab patients, respec-
tively, increased by 1 syringe/vial or shortened dosing frequency. Among con-
tinuing patients (1078 etanercept; 480 adalimumab; 819 infliximab), 6.0%, 16.9%,
and 29.1% of etanercept, adalimumab, and infliximab patients, respectively, had
2 instances of dose escalation (p0.0001 for all 2-way comparisons). Most con-
tinuing patients (93.5% etanercept; 95.6% adalimumab; N/A infliximab) received
the index dose at recommended dose; of these, 4.1%, 19.6%, and 79.5% of etaner-
cept, adalimumab, and infliximab patients, respectively, increased by 1 syringe/
vial or shortened dosing frequency. CONCLUSIONS: Etanercept had lower dose
escalation rates for new and continuing patients compared with adalimumab and
infliximab in a large US managed care plan.
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OBJECTIVES: The purpose of this study was to estimate the cost-effectiveness of
alendronate therapy for osteopenic postmenopausal women in Japan.METHODS:
A Markov model with six health states (no fracture, post-vertebral fracture, post-
hip fracture, post-vertebral and hip fracture, bedridden, and death) was developed
to predict lifetime costs and quality-adjusted life years (QALYs) of five years of
alendronate therapy versus no drug treatment in postmenopausal womenwithout
fracture history. Fracture risk associated with age and bone mineral density (BMD)
was derived from epidemiologic studies in Japan. We ran the model with different
combinations of age (65 to 75), BMD (70% - 80% of the young adultmean (YAM)), and
the number of clinical risk factors (CRFs, one to three). Probabilistic sensitivity
analysiswas performed to assess parameter uncertainty.RESULTS:Themodelwas
sensitive to age, BMD, and CRFs. The incremental cost-effectiveness ratio (ICER)
was below $50,000 per QALY in the following scenarios: 1) In 70-year-old women
with BMD 70% of YAM, who had two CRFs, 2) In 75-year-old women with BMD 70%
of YAM, who had two CRFs. In 65-year-old womenwith BMD 70% of YAM, who had
three CRFs, 3) In 70-year-oldwomenwith BMD 70% and 75% of YAM,who had three
CRFs, and 4) In 75-year-old women with BMD 70% and 75% of YAM, who had three
CRFs. Applying a willingness to pay threshold of $50,000 per QALY, the probability
of being cost-effective was estimated to 2.9 %, 36.5%, and 99.2% in 70-year-old
women with BMD 70% of YAM with one CRF, two CRFs, and three CRFs,
respectively. CONCLUSIONS: Whether to treat osteopenic postmenopausal Japa-
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